C. Kleoudis

2.6k total citations · 1 hit paper
25 papers, 1.8k citations indexed

About

C. Kleoudis is a scholar working on Rheumatology, Gastroenterology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, C. Kleoudis has authored 25 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Rheumatology, 8 papers in Gastroenterology and 7 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in C. Kleoudis's work include Systemic Lupus Erythematosus Research (12 papers), Gastrointestinal motility and disorders (7 papers) and Monoclonal and Polyclonal Antibodies Research (7 papers). C. Kleoudis is often cited by papers focused on Systemic Lupus Erythematosus Research (12 papers), Gastrointestinal motility and disorders (7 papers) and Monoclonal and Polyclonal Antibodies Research (7 papers). C. Kleoudis collaborates with scholars based in United States, United Kingdom and Belgium. C. Kleoudis's co-authors include David A. Roth, Beulah Ji, Z. John Zhong, Ronald van Vollenhoven, Ricard Cervera, Michelle Petri, William W. Freimuth, Richard Furie, Zahir Amoura and Brad H. Rovin and has published in prestigious journals such as New England Journal of Medicine, Gastroenterology and Pain.

In The Last Decade

C. Kleoudis

24 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis

2020 549 citations Richard Furie, Brad H. Rovin et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
C. Kleoudis United States	12	1.1k	786	552	329	322	25	1.8k
Frances Rees United Kingdom	12	1.0k 1.0×	499 0.6×	136 0.2×	384 1.2×	29 0.1×	19	1.6k
Maria Grazia Lazzaroni Italy	18	472 0.4×	327 0.4×	63 0.1×	238 0.7×	102 0.3×	71	1.2k
Kuntal Chakravarty United Kingdom	22	1.0k 0.9×	464 0.6×	62 0.1×	220 0.7×	46 0.1×	60	2.0k
Claudia Mendoza‐Pinto Mexico	25	896 0.8×	492 0.6×	117 0.2×	121 0.4×	12 0.0×	100	1.6k
Mohammed Yousuf Karim United Kingdom	22	707 0.7×	444 0.6×	138 0.3×	102 0.3×	10 0.0×	59	1.4k
Bünyamin Kısacık Türkiye	21	507 0.5×	303 0.4×	107 0.2×	273 0.8×	17 0.1×	108	1.7k
J. Rosas Spain	16	705 0.7×	231 0.3×	96 0.2×	499 1.5×	10 0.0×	51	1.8k
Michelle Petri United States	12	1.1k 1.0×	700 0.9×	181 0.3×	186 0.6×	12 0.0×	16	1.4k
Ana M. Bertoli United States	16	921 0.9×	460 0.6×	138 0.3×	48 0.1×	15 0.0×	40	1.1k
Graham Davenport United Kingdom	10	606 0.6×	242 0.3×	187 0.3×	317 1.0×	10 0.0×	21	1.0k

Countries citing papers authored by C. Kleoudis

Since Specialization

Citations

This map shows the geographic impact of C. Kleoudis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Kleoudis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Kleoudis more than expected).

Fields of papers citing papers by C. Kleoudis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Kleoudis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Kleoudis. The network helps show where C. Kleoudis may publish in the future.

Co-authorship network of co-authors of C. Kleoudis

This figure shows the co-authorship network connecting the top 25 collaborators of C. Kleoudis. A scholar is included among the top collaborators of C. Kleoudis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Kleoudis. C. Kleoudis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bruce, Ian N, Richard Furie, Eric F. Morand, et al.. (2022). Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials. Annals of the Rheumatic Diseases. 81(7). 962–969. 26 indexed citations

Werth, V., et al.. (2022). POS0367 IMPROVEMENT OF INDIVIDUAL MUCOCUTANEOUS MANIFESTATIONS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS TREATED WITH ANIFROLUMAB. Annals of the Rheumatic Diseases. 81. 436–437. 2 indexed citations

Furie, Richard, Brad H. Rovin, Frédéric Houssiau, et al.. (2020). Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. New England Journal of Medicine. 383(12). 1117–1128. 549 indexed citations breakdown →

Furie, Richard, Brad H. Rovin, F. Houssiau, et al.. (2020). OP0164 BLISS-LN: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL OF INTRAVENOUS BELIMUMAB IN PATIENTS WITH ACTIVE LUPUS NEPHRITIS. Annals of the Rheumatic Diseases. 79. 103–103. 11 indexed citations

Lapane, Kate L., et al.. (2017). Medicine Based Evidence for Individualized Decision Making: Case Study of Systemic Lupus Erythematosus. The American Journal of Medicine. 130(11). 1290–1297.e6. 8 indexed citations

Duke, Susan P., et al.. (2017). Quantitative Methods for Safety Monitoring of Rare Serious Adverse Events. Pharmaceutical Medicine. 31(2). 113–118. 3 indexed citations

Doria, Andrea, William Stohl, Andreas Schwarting, et al.. (2017). SAT0231 Safety of subcutaneous belimumab in patients with systemic lupus erythematosus: a 6-month open-label extension study. Annals of the Rheumatic Diseases. 76. 861–861. 3 indexed citations

Schmitt, Claude, David A. Roth, Helen L. Birch, C. Kleoudis, & JE de Vries. (2013). OP0115 Efficacy of Belimumab in Systemic Lupus Erythematosus Patients with High Disease Activity in Key Organ Systems: Bliss Sub-Populations. Annals of the Rheumatic Diseases. 72. A90–A90.

Vollenhoven, Ronald van, Michelle Petri, Ricard Cervera, et al.. (2012). Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Annals of the Rheumatic Diseases. 71(8). 1343–1349. 294 indexed citations

10.

Jansen, Jan‐Peter, Daniel Lorch, Ben Lasko, et al.. (2011). A Randomized, Placebo-Controlled Phase 3 Trial (Study SB-767905/012) of Alvimopan for Opioid-Induced Bowel Dysfunction in Patients With Non-Cancer Pain. Journal of Pain. 12(2). 185–193. 59 indexed citations

11.

Irving, Gordon, Brian Ramjattan, Michael J. Cousins, et al.. (2011). A Randomized, Placebo-Controlled Phase 3 Trial (Study SB-767905/013) of Alvimopan for Opioid-Induced Bowel Dysfunction in Patients With Non-Cancer Pain. Journal of Pain. 12(2). 175–184. 59 indexed citations

12.

Webster, Lynn R., John F. Peppin, Ben Lasko, et al.. (2008). Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: Results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain. Pain. 137(2). 428–440. 115 indexed citations

13.

Sabatowski, R., Anne M. Rentz, C. Kleoudis, et al.. (2006). 696 EFFECT OF ALVIMOPAN ON HEALTH‐RELATED QUALITY OF LIFE (HRQOL) IN SUBJECTS WITH OPIOID‐INDUCED GASTROINTESTINAL (GI) SIDE EFFECTS: THE PAC‐QOL QUESTIONNAIRE. European Journal of Pain. 10(S1). 3 indexed citations

14.

Talley, Nicholas J., George E. Dukes, T. Perschy, et al.. (2001). A dose‐ranging, placebo‐controlled, randomized trial of alosetron in patients with functional dyspepsia. Alimentary Pharmacology & Therapeutics. 15(4). 525–537. 94 indexed citations

15.

Kleoudis, C., et al.. (2001). Validation of adequate relief as an endpoint in clinical trials in functional dyspepsia. Gastroenterology. 120(5). A756–A756. 1 indexed citations

16.

Drossman, Douglas A., et al.. (2000). Alosetron does not improve anxiety in female IBS patients. Gastroenterology. 118(4). A616–A616. 5 indexed citations

17.

Sandborn, William J., William J. Tremaine, Douglas C. Wolf, et al.. (1999). Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. Gastroenterology. 117(3). 527–535. 180 indexed citations

18.

Rodriguez-Stanley, Sheila, Beverley Greenwood–Van Meerveld, Philip E. Jaffe, et al.. (1998). Heartburn Requiring Frequent Antacid Use May Indicate Significant Illness. Archives of Internal Medicine. 158(21). 2373–2373. 56 indexed citations

19.

Osato, Michael S., et al.. (1998). Development of clarithromycin resistance is 2.7 times less likely with ranitidine bismuth citrate than with omeprazole. Gastroenterology. 114. A249–A249. 7 indexed citations

20.

Gupta, Samir K., et al.. (1996). ETHANOL PHARMACODYNAMICS AT LOW BLOOD CONCENTRATIONS. American Journal of Therapeutics. 3(5). 375–382. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact